幹細胞治療の世界市場：治療タイプ、細胞源、エンドユーザー、用途、治療領域別-2025-2030年予測

幹細胞治療市場の2023年の市場規模は39億1,000万米ドルで、2024年には44億5,000万米ドル、CAGR14.27%で成長し、2030年には99億5,000万米ドルに達すると予測されています。

幹細胞治療は、現代医学において最も有望なフロンティアのひとつであり、再生治療と疾病管理に新たな道を開くものです。この革新的な分野では、幹細胞の特徴的な性質を利用して、損傷した組織を修復し、機能性を回復させ、従来の治療では不十分であった患者に希望を与えることができます。近年、幹細胞の基礎となる生物学的性質に関する広範な研究が進められ、変性疾患から急性損傷に至るまで、様々な疾患を対象とする画期的な治療法への道が開かれつつあります。

細胞の単離技術、培養法、ゲノムのプロファイリングが絶え間なく改良され、これらの治療法の安全性と有効性が高まっただけでなく、応用の可能性も広がっています。科学界と規制機関がより緊密に連携し、その枠組みやプロトコルを確立するにつれ、幹細胞技術を主流ヘルスケアに組み込むことが、ますます現実味を帯びてきています。このイントロダクションは、新たな動向や技術の進歩が、どのように医療情勢を再構築し、個別化医療や再生医療の新時代を切り開こうとしているのかについて、より広範な議論を展開するための舞台を提供するものです。

学際的な研究を受け入れ、官民のパートナーシップを育み、確固たる臨床検証を維持することで、幹細胞治療市場は、かつては手の届かないものと考えられていた臨床現場と患者の転帰の両方を変革する態勢を整えています。

幹細胞治療市場の変革

近年、幹細胞治療を取り巻く環境は、急速な科学的進歩と進化する市場力学に後押しされ、大きく変化しています。最先端のバイオテクノロジーの統合によって、実験段階から臨床的に承認された治療法への移行が促進され、多様な医療分野にわたる治療戦略が再定義されました。細胞の初期化、培養条件の向上、精密医療における革新的な手法は総体的に、個別化医療が具体的な現実となりつつあるパラダイムシフトに貢献しています。

この進化は、幹細胞の挙動に関するより深い科学的理解によって支えられており、その結果、研究者たちは細胞の生存能力や分化に関するこれまでの限界を克服することができるようになりました。調査や臨床試験の結果、同種幹細胞、自家幹細胞、人工多能性幹細胞、周産期幹細胞など、多様な細胞源を利用することの重要性が浮き彫りになってきました。

厳密な規制経路の出現と技術の進歩は、利害関係者に自信を与え続けています。経済的な考慮、資金調達の機会、戦略的な協力関係などが、この分野における技術革新のペースをさらに加速させています。市場促進要因が集約された結果、より弾力性があり、データ主導型で、再生医療を通じて複雑なヘルスケアの課題に対処できる産業が生まれます。

幹細胞治療の包括的な市場セグメンテーションの洞察

市場セグメンテーションのニュアンスを理解することは、幹細胞治療の複雑なエコシステムをナビゲートするために不可欠です。市場分析は、治療法や研究用途の多様性を定量化する複数のセグメンテーション要因によって推進されます。主要なセグメンテーションのひとつは、治療のタイプに基づくもので、同種移植と自家移植の両方のアプローチで市場を評価することができます。ドナーから幹細胞を得るか、患者自身から幹細胞を得るかによって、それぞれの治療法には明確な利点があり、それによって安全性、有効性、個別化された治療法が左右されます。

第二の重要な側面は、細胞源に基づく研究です。この調査では、成体幹細胞、胚性幹細胞、人工多能性幹細胞、周産期幹細胞を調査し、それぞれの治療の可能性と限界を明らかにします。成体幹細胞は、特に造血幹細胞、間葉系幹細胞、神経幹細胞の研究を通して、さらなる分析的注目を浴びています。同様に、周産期の幹細胞は、羊水、胎盤、臍帯の由来を評価することで精査されます。このように細かく分類することで、各細胞タイプの相対的なメリットや臨床応用可能性についての洞察が得られます。

市場はさらに、学術・研究機関、バイオテクノロジー・製薬企業、病院・専門クリニックといったエンドユーザー・セグメントによって区分されます。このようなセグメンテーションは、研究革新、治療開発、患者中心の治療モデルに対するさまざまな要求を反映しています。さらに、用途別のセグメンテーションでは、創薬や開発、再生医療、組織工学などにおける幹細胞治療の活用が強調されています。もう一つのセグメンテーション領域は治療分野に焦点を当て、心臓血管疾患、血液学、筋骨格系疾患、神経疾患、腫瘍学が再生治療の主要なターゲットです。この多角的な分析は、幹細胞研究の応用範囲の広さを浮き彫りにするだけでなく、特定の医療課題に対処するために必要とされる個別化されたアプローチを強調しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界の高齢化と幹細胞の治療可能性に対する認識の高まり
    • 政府の取り組みと有利な規制枠組みが幹細胞調査の進歩を促進している
    • 慢性疾患の増加により、高度な幹細胞治療の必要性が高まっています。
  • 抑制要因
    • 幹細胞治療に関連する高コストは、患者と医療提供者の両方のアクセスを制限します
  • 機会
    • 研究開発活動への公的および民間投資の増加
    • 細胞ベースの技術の進歩により、幹細胞療法の有効性と応用性が向上しています。
  • 課題
    • 幹細胞治療に関するさまざまな規制状況への対応
    • 幹細胞の使用をめぐる倫理的な懸念と国民の認識
• 市場セグメンテーション分析
  • 治療の種類：免疫拒絶や感染症の伝染のリスクを最小限に抑えるため、自己免疫性疾患の治療の適用が拡大しています。
  • 細胞源：中枢神経系内の様々な細胞型に分化する能力による神経幹細胞の増殖の重要性
  • エンドユーザー：神経変性疾患や心血管疾患に対処するためにバイオテクノロジーおよび製薬企業で幹細胞治療の採用が増加
  • 応用：疾患モデル化能力により、創薬および開発における応用が増加
  • 治療領域：心臓の修復と再生による心血管疾患における幹細胞治療の大きな利点
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 幹細胞治療市場治療の種類別

• 同種療法
• 自家移植療法

第7章 幹細胞治療市場セルソース

• 成体幹細胞
  • 造血幹細胞
  • 間葉系幹細胞
  • 神経幹細胞
• 胚性幹細胞
• 誘導多能性幹細胞
• 周産期幹細胞
  • 羊水幹細胞
  • 胎盤幹細胞
  • 臍帯幹細胞

第8章 幹細胞治療市場：エンドユーザー別

• 学術調査機関
• バイオテクノロジーおよび製薬会社
• 病院と専門クリニック

第9章 幹細胞治療市場：用途別

• 医薬品の発見と開発
• 再生医療
• 組織工学

第10章 幹細胞治療市場治療領域別

• 心血管疾患
• 血液学
• 筋骨格系障害
• 神経疾患
• 腫瘍学

第11章 南北アメリカの幹細胞治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の幹細胞治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの幹細胞治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Anterogen Co., Ltd.
• Astellas Pharma Inc.
• Beike Biotechnology Co., Ltd.
• BrainStorm Cell Therapeutics Inc.
• Bristol-Myers Squibb Company
• CellProthera SAS
• Fate Therapeutics, Inc.
• Gamida Cell Ltd.
• Garuda Therapeutics
• Holostem Terapie Avanzate S.r.l.
• Jasper Therapeutics, Inc.
• JCR Pharmaceuticals Co., Ltd.
• Juvena Therapeutics Inc.
• Kangstem Biotech Co., Ltd.
• Kite Pharma, Inc. by Gilead Sciences, Inc.
• Lonza Group AG
• Medeze Group
• Merck KGaA
• Mesoblast Ltd.
• Novo Nordisk A/S
• Plasticell
• ReNeuron Group PLC
• SQZ Biotechnologies Company by Stemcell Technologies
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• U.S. Stem Cell Inc
• Umoja Biopharma
• Vericel Corporation

LIST OF FIGURES

• FIGURE 1. STEM CELL THERAPY MARKET MULTI-CURRENCY
• FIGURE 2. STEM CELL THERAPY MARKET MULTI-LANGUAGE
• FIGURE 3. STEM CELL THERAPY MARKET RESEARCH PROCESS
• FIGURE 4. STEM CELL THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. STEM CELL THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PLACENTAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 59. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 61. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 62. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 63. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 96. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 98. CHINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 99. CHINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 100. CHINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. CHINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. CHINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 103. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 105. INDIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 106. INDIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 107. INDIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. INDIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. INDIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 223. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 225. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 226. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 227. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 228. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 251. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. POLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 253. POLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 254. POLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 255. POLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 256. POLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 257. POLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 258. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. QATAR STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 260. QATAR STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 261. QATAR STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 262. QATAR STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 263. QATAR STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 264. QATAR STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
• TABLE 328. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 329. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Stem Cell Therapy Market was valued at USD 3.91 billion in 2023 and is projected to grow to USD 4.45 billion in 2024, with a CAGR of 14.27%, reaching USD 9.95 billion by 2030.

Stem cell therapy represents one of the most promising frontiers in modern medicine, opening new avenues for regenerative treatments and disease management. This innovative field harnesses the distinctive properties of stem cells to repair damaged tissues, restore functionality, and offer patients hope where conventional treatments may fall short. In recent years, extensive research has driven a better understanding of the underlying biology of stem cells, paving the way for breakthrough therapies that target a range of conditions from degenerative disorders to acute injuries.

The continuous refinement in cell isolation techniques, culture methods, and genomic profiling has not only increased the safety and efficacy of these therapies but also expanded their potential applications. As the scientific community and regulatory bodies work more closely to establish frameworks and protocols, the integration of stem cell technology into mainstream healthcare is becoming increasingly feasible. This introduction sets the stage for a broader discussion on how emerging trends and technological advances are reshaping the landscape, ushering in a new era of personalized and regenerative medicine.

By embracing interdisciplinary research, fostering public and private partnerships, and maintaining robust clinical validations, the stem cell therapy market is poised to transform both clinical practices and patient outcomes in a manner that was once considered out of reach.

Transformative Shifts in the Stem Cell Therapy Landscape

Recent years have been marked by transformative shifts in the landscape of stem cell therapy, driven by rapid scientific advancements and evolving market dynamics. The integration of state-of-the-art biotechnologies has facilitated the progression from experimental phases to clinically approved treatments, thereby redefining therapeutic strategies across diverse medical disciplines. Innovative methods in cell reprogramming, enhanced culture conditions, and precision medicine have collectively contributed to a paradigm shift where personalized care is becoming a tangible reality.

This evolution is underpinned by a deeper scientific understanding of stem cell behavior that has enabled researchers to overcome previous limitations related to cell viability and differentiation. Research and clinical trials have not only highlighted the therapeutic potential of both allogeneic and autologous approaches but have also underscored the importance of harnessing varied cell sources such as adult, embryonic, induced pluripotent, and perinatal stem cells.

The emergence of rigorous regulatory paths, combined with technological advancements, continues to instill confidence in stakeholders. Economic considerations, funding opportunities, and strategic collaborations are further accelerating the pace of innovation in this sector. As market drivers converge, the result is an industry that is more resilient, data-driven, and capable of addressing complex healthcare challenges through regenerative medicine.

Comprehensive Market Segmentation Insights in Stem Cell Therapy

Understanding the nuances of market segmentation is critical to navigating the complex ecosystem of stem cell therapy. The market analysis is driven by multiple segmentation factors that quantify the diversity in treatment modalities and research applications. One primary segmentation is based on therapy type, where the market is evaluable both under allogeneic and autologous approaches. Each method brings distinct advantages, whether deriving stem cells from donors or patients themselves, thereby influencing safety, efficacy, and personalized treatment options.

A second pivotal dimension is the investigation based on cell source. The research examines adult stem cells, embryonic stem cells, induced pluripotent stem cells, and perinatal stem cells to discern their therapeutic potential and limitations. Adult stem cells receive further analytical attention, particularly through the study of hematopoietic, mesenchymal, and neural stem cells, each contributing unique properties that influence treatment outcomes. Similarly, perinatal stem cells are scrutinized by evaluating amniotic fluid, placental, and umbilical cord sources. This granular breakdown provides insights into the relative merits and clinical applicability of each cell type.

The market is further divided according to end user segments-academic and research institutions, biotechnology and pharmaceutical companies, and hospitals and specialty clinics. Such segmentation reflects the varying demands for research innovation, therapy development, and patient-centered treatment models. Additionally, the application-based segmentation emphasizes the utilization of stem cell therapies in drug discovery and development, regenerative medicine, and tissue engineering. Another segmentation area focuses on therapeutic areas, where cardiovascular diseases, hematology, musculoskeletal disorders, neurological disorders, and oncology are the primary targets of regenerative interventions. This multidimensional analysis not only highlights the expansive application of stem cell research but also underscores the tailored approaches that are required to address specific medical challenges.

Based on Therapy Type, market is studied across Allogeneic Therapy and Autologous Therapy.

Based on Cell Source, market is studied across Adult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells, and Perinatal Stem Cells. The Adult Stem Cells is further studied across Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Neural Stem Cells. The Perinatal Stem Cells is further studied across Amniotic Fluid Stem Cells, Placental Stem Cells, and Umbilical Cord Stem Cells.

Based on End User, market is studied across Academic & Research Institutions, Biotechnology & Pharmaceutical Companies, and Hospitals & Specialty Clinics.

Based on Application, market is studied across Drug Discovery and Development, Regenerative Medicine, and Tissue Engineering.

Based on Therapeutic Areas, market is studied across Cardiovascular Diseases, Hematology, Musculoskeletal Disorders, Neurological Disorders, and Oncology.

Global Regional Dynamics in the Stem Cell Therapy Market

Regional dynamics play a crucial role in mapping the global landscape of stem cell therapy. Market trends and regulatory approvals exhibit distinct patterns across different regions. In the Americas, robust investment in biomedical research and well-established healthcare infrastructures are significant drivers for the adoption of advanced stem cell therapies. The region's diverse population and proactive public-private partnerships have spurred rapid development and clinical trials that continue to influence global standards.

Meanwhile, in regions encompassing Europe, the Middle East, and Africa, a blend of tradition and innovation is pushing forward progressive healthcare agendas. Researchers and policymakers in these areas are increasingly focused on developing localized therapies that address region-specific health challenges while aligning with international protocols. The strengthening of regulatory frameworks in these regions further supports the safe and effective integration of stem cell therapies into routine clinical practice.

In the Asia-Pacific region, rapid economic growth combined with a significant increase in research funding has positioned the area as a burgeoning hub for biotechnology and regenerative medicine. Driven by expansive clinical research, technological adoption, and a rising middle-class demand for advanced healthcare solutions, the Asia-Pacific markets are progressively adopting novel stem cell therapies. This tripartite regional overview provides a comprehensive understanding of how local trends, regulatory environments, and economic factors interplay to shape the global market landscape of stem cell therapy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Steering Stem Cell Therapy Advancements

Numerous pioneering companies are at the vanguard of driving advancements in the stem cell therapy space. Industry leaders such as Anterogen Co., Ltd. and Astellas Pharma Inc. are continuously adopting innovative approaches to developing breakthrough therapies. These companies, along with emerging innovators like Beike Biotechnology Co., Ltd. and BrainStorm Cell Therapeutics Inc., are instrumental in translating cutting-edge research into clinically effective solutions. Notable pharmaceutical giants like Bristol-Myers Squibb Company and Kite Pharma, Inc. under Gilead Sciences, Inc. have also contributed significantly by leveraging their extensive research networks and global resources to propel stem cell therapies forward.

Other prominent market players, including CellProthera SAS, Fate Therapeutics, Inc., and Gamida Cell Ltd., are recognized for their focus on enhancing the differentiation processes and ensuring consistent quality across therapeutic applications. Companies such as Garuda Therapeutics and Holostem Terapie Avanzate S.r.l. have further diversified the landscape by exploring novel cell sources and addressing unmet clinical needs. Jasper Therapeutics, Inc. and JCR Pharmaceuticals Co., Ltd. are continuously pushing the envelope for clinical innovation, while Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., and Lonza Group AG play critical roles by ensuring the scalability and reliability of stem cell production.

In addition, organizations like Medeze Group, Merck KGaA, and Mesoblast Ltd. are investing in research and development to establish next-generation treatment protocols. Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, and SQZ Biotechnologies Company by Stemcell Technologies are leveraging the latest in cellular engineering to expand therapeutic frontiers. Finally, companies such as Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc., Umoja Biopharma, and Vericel Corporation round out the comprehensive list of key players whose consistent innovation and market presence are setting the pace for the future of stem cell therapy. Each of these companies not only contributes technological expertise and clinical experience but also serves as a benchmark for excellence in advancing regenerative medicine.

The report delves into recent significant developments in the Stem Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Astellas Pharma Inc., Beike Biotechnology Co., Ltd., BrainStorm Cell Therapeutics Inc., Bristol-Myers Squibb Company, CellProthera SAS, Fate Therapeutics, Inc., Gamida Cell Ltd., Garuda Therapeutics, Holostem Terapie Avanzate S.r.l., Jasper Therapeutics, Inc., JCR Pharmaceuticals Co., Ltd., Juvena Therapeutics Inc., Kangstem Biotech Co., Ltd., Kite Pharma, Inc. by Gilead Sciences, Inc., Lonza Group AG, Medeze Group, Merck KGaA, Mesoblast Ltd., Novo Nordisk A/S, Plasticell, ReNeuron Group PLC, SQZ Biotechnologies Company by Stemcell Technologies, Takara Bio Inc., Thermo Fisher Scientific Inc., U.S. Stem Cell Inc, Umoja Biopharma, and Vericel Corporation. Strategic Recommendations for Maximizing Growth in Stem Cell Therapy

In an evolving industry characterized by rapid advancements and regulatory complexities, industry leaders must adopt strategic measures to sustain growth in the field of stem cell therapy. First, it is essential to continuously invest in research and development to not only improve the therapeutic efficiency of existing modalities but also to discover novel approaches that could address emerging clinical challenges. Maintaining strong collaborations with academic research institutions and global biotechnological networks will enable companies to stay at the forefront of innovation.

Second, companies should prioritize the implementation of rigorous quality control measures and standardized manufacturing processes. This approach will ensure safety, enhance scalability, and promote regulatory compliance throughout the entire production lifecycle. Embracing digital transformations-such as integrating data analytics and artificial intelligence into research pipelines-could provide sharper insights into clinical outcomes and operational efficiencies.

Third, industry stakeholders must tailor their strategies to the unique demands of different regional markets. Customized solutions that account for local regulatory frameworks and market maturity can significantly enhance market penetration and clinical acceptance. It is equally important to build strong, trust-based relationships with healthcare providers by offering continuous education, technical support, and transparent communication regarding the benefits and limitations of various therapies.

Finally, proactive engagement with regulatory bodies is crucial. Keeping abreast of policy changes and participating in shaping future guidelines can preempt regulatory challenges and facilitate smoother market entry. By combining innovation, operational excellence, and strategic regional focus, companies can effectively navigate the competitive landscape and drive sustained growth in the therapeutic domain.

Executive Summary Conclusion: The Future of Stem Cell Therapy

As the stem cell therapy market matures, the convergence of technological breakthroughs, evolving regulatory landscapes, and comprehensive segmentation strategies has painted a promising outlook for the future of regenerative medicine. The journey from laboratory innovation to clinical application is now marked by transformative shifts that are reshaping the standards of care in diverse therapeutic areas. From the rigorous analysis of therapy types and cell sources to the dynamic influence of regional markets and the relentless pursuit of technological excellence by key industry players, every facet of this ecosystem has contributed to building a robust, scalable, and patient-centric therapeutic paradigm.

The continuous evolution of therapeutic strategies coupled with strategic collaborations is further cementing the role of stem cell therapy as an essential component in modern medical practice. As clinical trials yield increasingly positive results and regulatory pathways become more clearly defined, the potential to address complex health issues with precision medicine grows stronger every day. Stakeholders are now presented with a unique opportunity to not only capitalize on these advancements but also to drive the next wave of clinical innovations that could redefine treatment protocols across boundaries.

In summary, the strategic foresight, collaborative efforts, and unwavering commitment to excellence in research and development are setting the stage for breakthroughs that will transform patient care globally. The industry is poised on the brink of a new era, one that promises to deliver enhanced therapeutic outcomes and improved quality of life for patients worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising aging global population and awareness about the therapeutic potential of stem cells
    • 5.1.1.2. Government initiatives and favorable regulatory frameworks are promoting stem cell research advancement
    • 5.1.1.3. Growing prevalence of chronic diseases is fueling the need for advanced stem cell therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with stem cell therapy limit accessibility for both patients and providers
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing public and private investment in research and development activities
    • 5.1.3.2. Advancements in cell-based technologies are enhancing the efficacy and applications of stem cell therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Navigating the varying regulatory landscape for stem cell therapies
    • 5.1.4.2. Ethical concerns and public perception surrounding the use of stem cells
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy Type: Growing applications of autologous therapy owing to minimizing the risk of immune rejection and transmission of infectious diseases
  • 5.2.2. Cell Source: Proliferating significance of neural stem cells due to the ability to differentiate into various cell types within the central nervous system
  • 5.2.3. End User: Increasing adoption of stem cell therapy in biotechnology & pharmaceutical companies for addressing neurodegenerative diseases and cardiovascular disorders
  • 5.2.4. Application: Rising applications in drug discovery and development owing to their ability to model diseases
  • 5.2.5. Therapeutic Areas: Significant benefits of stem cell therapy in cardiovascular diseases owing to cardiac repair and regeneration
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Stem Cell Therapy Market, by Therapy Type

• 6.1. Introduction
• 6.2. Allogeneic Therapy
• 6.3. Autologous Therapy

7. Stem Cell Therapy Market, by Cell Source

• 7.1. Introduction
• 7.2. Adult Stem Cells
  • 7.2.1. Hematopoietic Stem Cells
  • 7.2.2. Mesenchymal Stem Cells
  • 7.2.3. Neural Stem Cells
• 7.3. Embryonic Stem Cells
• 7.4. Induced Pluripotent Stem Cells
• 7.5. Perinatal Stem Cells
  • 7.5.1. Amniotic Fluid Stem Cells
  • 7.5.2. Placental Stem Cells
  • 7.5.3. Umbilical Cord Stem Cells

8. Stem Cell Therapy Market, by End User

• 8.1. Introduction
• 8.2. Academic & Research Institutions
• 8.3. Biotechnology & Pharmaceutical Companies
• 8.4. Hospitals & Specialty Clinics

9. Stem Cell Therapy Market, by Application

• 9.1. Introduction
• 9.2. Drug Discovery and Development
• 9.3. Regenerative Medicine
• 9.4. Tissue Engineering

10. Stem Cell Therapy Market, by Therapeutic Areas

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
• 10.3. Hematology
• 10.4. Musculoskeletal Disorders
• 10.5. Neurological Disorders
• 10.6. Oncology

11. Americas Stem Cell Therapy Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Stem Cell Therapy Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Stem Cell Therapy Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. REGiMMUNE and Kiji Therapeutics unite to advance Treg-focused stem cell therapies
  • 14.3.2. Evotec and Novo Nordisk partnership advances stem cell therapy innovations for scalable solutions
  • 14.3.3. Collaboration between Somite Therapeutics and OmniaBio Inc. aims to revolutionize stem cell therapy with AI-driven approaches for Duchenne muscular dystrophy
  • 14.3.4. Bioserve India's launch of advanced stem cell products propels innovative research and therapies in India's regenerative medicine landscape
  • 14.3.5. Cell BioEngines secures USD 2 million funding to advance 'off-the-shelf' hematopoietic stem cell therapies and initiate multicenter clinical trials
  • 14.3.6. OrganaBio revolutionizes advanced therapy development with on-demand GMP-compliant hematopoietic stem cells
  • 14.3.7. FDA expands approval for CARVYKTI as the first BCMA-targeted therapy advancing multiple myeloma treatment
  • 14.3.8. Strategic partnership accelerates stem cell therapy development through streamlined collaboration
  • 14.3.9. Fujifilm to Invest USD 200 Million in Cell Therapy Production
  • 14.3.10. Mesoblast Enters Collaboration for SR-aGVHD Trial After FDA Rejections
  • 14.3.11. Merger between Selecta Biosciences and Cartesian Therapeutics pioneers RNA cell therapy advancements
  • 14.3.12. Takara Bio Enters into a License Agreement of RetroNectin with Fondazione Telethon ETS
  • 14.3.13. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale
  • 14.3.14. Novo Nordisk Foundation Invests USD 135 Million to Build Cell Therapy Plant
  • 14.3.15. BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
  • 14.3.16. BlueRock Therapeutics and bit.bio Announce Collaboration and Option Agreement for the Discovery and Manufacture of Regulatory T Cell (Treg) based Therapies
  • 14.3.17. StemCyte Signs a Cooperation Agreement with a Cutting-edge U.S. immune Cell Therapy Company to Supply Drug Preparation Raw Materials for Allogeneic Modified Cell Therapy
  • 14.3.18. CIRM Invests USD 89 Million in Stem Cell and Gene Therapy Research
  • 14.3.19. Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
  • 14.3.20. Novo Nordisk to Expand R&D Presence in Greater Boston Area
  • 14.3.21. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
  • 14.3.22. BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
  • 14.3.23. ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Player in Regenerative Therapies
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 14.4.2. JCR Pharmaceuticals Co., Ltd.
  • 14.4.3. Novo Nordisk A/S
  • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

• 1. Anterogen Co., Ltd.
• 2. Astellas Pharma Inc.
• 3. Beike Biotechnology Co., Ltd.
• 4. BrainStorm Cell Therapeutics Inc.
• 5. Bristol-Myers Squibb Company
• 6. CellProthera SAS
• 7. Fate Therapeutics, Inc.
• 8. Gamida Cell Ltd.
• 9. Garuda Therapeutics
• 10. Holostem Terapie Avanzate S.r.l.
• 11. Jasper Therapeutics, Inc.
• 12. JCR Pharmaceuticals Co., Ltd.
• 13. Juvena Therapeutics Inc.
• 14. Kangstem Biotech Co., Ltd.
• 15. Kite Pharma, Inc. by Gilead Sciences, Inc.
• 16. Lonza Group AG
• 17. Medeze Group
• 18. Merck KGaA
• 19. Mesoblast Ltd.
• 20. Novo Nordisk A/S
• 21. Plasticell
• 22. ReNeuron Group PLC
• 23. SQZ Biotechnologies Company by Stemcell Technologies
• 24. Takara Bio Inc.
• 25. Thermo Fisher Scientific Inc.
• 26. U.S. Stem Cell Inc
• 27. Umoja Biopharma
• 28. Vericel Corporation